Access the full text.
Sign up today, get DeepDyve free for 14 days.
U. Bergmann, H. Funatomi, M. Yokoyama, H. Beger, M. Korc (1995)
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles.Cancer research, 55 10
Malcolm, J. Moore, John Andersen, Mark Green, M. Rothenberg, M. Modiano, M. Cripps, Russell, K. Portenoy, A. Storniolo, Peter Tarassoff, Robert Nelson, F. Dorr, C. Stephens, Daniel, D., Von Hoff (1997)
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
E. Ohmura, M. Okada, N. Onoda, Y. Kamiya, H. Murakami, T. Tsushima, K. Shizume (1990)
Insulin-like Growth Factor I and Transforming Growth Factor α as Autocrine Growth Factors in Human Pancreatic Cancer Cell GrowthCancer Research, 50
C. Louvet, R. Labianca, P. Hammel, G. Lledo, M. Zampino, T. André, A. Zaniboni, M. Ducreux, E. Aitini, J. Taieb, R. Faroux, C. Lepère, A. Gramont (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 15
D. Dunne, Derek McWhirter, G. Poston (2016)
Hormonal therapy in cancer
H. Riess, U. Pelzer, G. Deutschinoff, B. Opitz, M. Stauch, P. Reitzig, S. Hahnfeld, A. Hilbig, J. Stieler, H. Oettle (2009)
A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
PA Thodiyil, AK Kakkar (2002)
Variation in relative risk of venous thromboembolism in different cancersJ Thromb Heamost, 2
M. Moore, D. Goldstein, J. Hamm, A. Figer, J. Hecht, S. Gallinger, H. Au, P. Murawa, D. Walde, R. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, Mieke Ptasynski, W. Parulekar (2023)
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 41
M. Pollak (2008)
Insulin and insulin-like growth factor signalling in neoplasiaNature Reviews Cancer, 8
H. Kindler, L. Garbo, J. Stephenson, J. Wiezorek, T. Sabin, M. Hsu, F. Civoli, D. Richards (2009)
A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
P. Neuhaus, H. Riess, S. Post, K. Gellert, K. Ridwelski, H. Schramm, C. Zuelke, J. Fahlke, J. Langrehr, C. Burkart, H. Oettle (2008)
CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)Journal of Clinical Oncology, 26
J. Neoptolemos, D. Stocken, H. Friess, C. Bassi, J. Dunn, H. Hickey, H. Beger, L. Fernández‐Cruz, C. Dervenis, F. Lacaine, M. Falconi, P. Pederzoli, Á. Pap, D. Spooner, D. Kerr, M. Büchler (2004)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.The New England journal of medicine, 350 12
V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Schönekäs, A. Rost, H. Neuhaus, C. Haag, M. Clemens, B. Heinrich, U. Vehling‐Kaiser, M. Fuchs, D. Fleckenstein, W. Gesierich, D. Uthgenannt, H. Einsele, A. Holstege, A. Hinke, A. Schalhorn, R. Wilkowski (2006)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 24
G. Colucci, R. Labianca, F. Costanzo, V. Gebbia, G. Cartenì, B. Massidda, L. Frontini, M. Falconi, C. Gallo, M. Maio (2009)
A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
(2005)
PHASE III RANDOMISED COMPARISON OF GEMCITABINE (GEM) WITH GEMCITABINE PLUS CAPECITABINE (GEM-CAP) IN PATIENTS WITH ADVANCED PANCREATIC CANCER
J. Neoptolemos, M. Buchler, Deborah Stocken, P. Ghaneh, David Smith, C. Bassi, M. Moore, David Cunningham, C. Dervenis, D. Goldstein (2009)
ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
V. Heinemann, S. Boeck, A. Hinke, R. Labianca, C. Louvet (2008)
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 8
M. Pollak, M. Pollak, J. Perdue, J. Perdue, R. Margolese, R. Margolese, K. Baer, K. Baer, M. Richard, M. Richard (1987)
Presence of somatomedin receptors on primary human breast and colon carcinomas.Cancer letters, 38 1-2
Ovkojqskmfx çnNM, Pskr ãÖLïÉÉâ, Eovknjqrkuf åÇ, Ñçê éäÅÉÄç, Pskm ãÖLïÉÉâ, Eouksjqrknfk ëÉêìã, ÅçåÅÉåíêíáçå çnNM, ÇìêáåÖ çnNM (2002)
Variation in Relative Risk of Venous Thromboembolism in Different CancersThrombosis and Haemostasis, 87
The publication of practice changing clinical data is a rare event in the field of pancreatic cancer. In line with this general statement, oncologists attending or following the ASCO Annual Meeting 2009 were not surprised by being confronted with the study results mainly confirming the already existing evidence. The following conference report will therefore in its first part cover the results of the most important clinical phase III-trials presented. The ESPAC 3(v2)-study established 5-Fluorouracil (5-FU) as an equally effective but more toxic alternative to gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer. Concerning the palliative treatment of advanced disease the Italian GIP-1-study provided us with another set of data comparing gemcitabine with a gemcitabine/platinum-duplet, once again failing to document a survival benefit. The CONKO-004-study investigated the prophylactic application of a low-molecular-weight heparin (enoxaparin) in patients treated with chemotherapy for advanced pancreatic cancer. As one would expect, the rate of symptomatic venous thromboembolic events with this intervention was reduced. Whether this will translate into a survival benefit remains to be established, as the final analysis of this trial is still pending. Due to the paucity of presentations with further immediate practical relevance the second part of this short review will touch on two exciting abstracts dealing with the search for new therapeutic concepts, drugs and targets.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jan 12, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.